Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Authors:
- Andrew D ZaleAZAndrew D Zale
- Venkata Preetam Sandeep KaduluriVKVenkata Preetam Sandeep Kaduluri
- Jonathan A WebsterJWJonathan A Webster
- Mark J LevisMLMark J Levis
- Ivana GojoIGIvana Gojo
- Amy E DeZernADAmy E DeZern
- Gabriel GhiaurGGGabriel Ghiaur
- Lukasz P GondekLGLukasz P Gondek
- William Brian DaltonWDWilliam Brian Dalton
- Theodoros KarantanosTheodoros Karantanos
- Tania JainTJTania Jain
Open Access
- 1 July 2025
- journal article
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (4) , 100133
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsBlood, 2024
- Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLBlood, 2024
- Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemiaAmerican Journal of Hematology, 2024
- Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidineBlood, 2022
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNBlood, 2022
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Age and acute myeloid leukemiaBlood, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987